Markus Menzen
Overview
Explore the profile of Markus Menzen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudofsky G, Menzen M, Potier L, Catarig A, Clark A, Priyadarshini P, et al.
Adv Ther
. 2024 Dec;
42(2):788-800.
PMID: 39636564
Introduction: To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice. Methods: This post hoc...
2.
Yale J, Major-Pedersen A, Catarig A, Jain R, Menzen M, Holmes P
Diabetes Obes Metab
. 2024 Aug;
26(10):4429-4440.
PMID: 39118222
Aim: To investigate, through post hoc analysis of nine studies from the SemaglUtide Real-world Evidence (SURE) programme, the safety of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D)...
3.
Aberle J, Lautenbach A, Meyhofer S, Meyhofer S, Menzen M, Selig L, et al.
Exp Clin Endocrinol Diabetes
. 2024 Mar;
132(5):232-239.
PMID: 38452792
No abstract available.
4.
Menzen M
Dtsch Med Wochenschr
. 2023 Mar;
148(6):288-293.
PMID: 36878226
Medical progress is increasingly characterized by digital and technical solutions that improve and facilitate treatment of our patients. Especially diabetes therapy is an ideal field for digital and technical solutions....
5.
Menzen M, Berentzen T, Catarig A, Pieperhoff S, Simon J, Jacob S
Exp Clin Endocrinol Diabetes
. 2023 Jan;
131(4):205-215.
PMID: 36599459
Context: Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care....
6.
Aberle J, Menzen M, Schmid S, Terkamp C, Jaeckel E, Rohwedder K, et al.
Sci Rep
. 2020 Dec;
10(1):22396.
PMID: 33372185
Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis...
7.
Molderings G, Zienkiewicz T, Homann J, Menzen M, Afrin L
F1000Res
. 2017 Dec;
6:1889.
PMID: 29225779
It has been shown repeatedly that mast cells can promote or prevent cancer development and growth. If development and/or progression of a solid cancer is substantially influenced by mast cell...
8.
Altmuller J, Haenisch B, Kawalia A, Menzen M, Nothen M, Fier H, et al.
Immunogenetics
. 2017 Apr;
69(6):359-369.
PMID: 28386644
Mast cell activation syndrome (MCAS) and systemic mastocytosis (SM) are two clinical systemic mast cell activation disease variants. Few studies to date have investigated the genetic basis of MCAS. The...
9.
Molderings G, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin F, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2016 May;
389(7):671-94.
PMID: 27132234
Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation...
10.
Kaufmann D, Walkenbach K, Dohler N, Wagemann G, Menzen M, Homann J, et al.
Med Monatsschr Pharm
. 2011 Mar;
34(2):55-60.
PMID: 21428016
No abstract available.